Abstract: Nano structures having a core and a shell such as a lipid layer and optionally a lipoprotein which are useful for delivering nitric oxide are provided herein. Methods of treating disease using the nanostructures are also provided, including methods of treating vascular diseases, angiogenesis, ischemia-reperfusion, etc.

Abstract: Controlled release vascular implants, such as vascular grafts, stents, wraps, and gels comprising a biocompatible polymer and all trans retinoic acid (ATRA), or its derivatives, can be used to treat, prevent, or inhibit thrombosis and/or neointimal hyperplasia which may otherwise be induced by prosthetic implantation. In particular, the implants herein can inhibit smooth muscle cell proliferation, neointimal hyperplasia, and upregulate antithrombotic genes and nitric oxide production in the vasculature. Further, the implants are capable of delivering controlled and predictable localized concentrations of ATRA.

Abstract: Controlled release vascular implants, such as vascular grafts, stents, wraps, and gels comprising a biocompatible polymer and all trans retinoic acid (ATRA), or its derivatives, can be used to treat, prevent, or inhibit thrombosis and/or neointimal hyperplasia which may otherwise be induced by prosthetic implantation. In particular, the implants herein can inhibit smooth muscle cell proliferation, neointimal hyperplasia, and upregulate antithrombotic genes and nitric oxide production in the vasculature. Further, the implants are capable of delivering controlled and predictable localized concentrations of ATRA.

Abstract: Controlled release vascular implants, such as vascular grafts, stents, wraps, and gels comprising a biocompatible polymer and all trans retinoic acid (ATRA), or its derivatives, can be used to treat, prevent, or inhibit thrombosis and/or neointimal hyperplasia which may otherwise be induced by prosthetic implantation. In particular, the implants herein can inhibit smooth muscle cell proliferation, neointimal hyperplasia, and upregulate antithrombotic genes and nitric oxide production in the vasculature. Further, the implants are capable of delivering controlled and predictable localized concentrations of ATRA.

Abstract: Disclosed herein is a biodegradable nitric oxide-generating polymer comprising a nitric oxide-releasing N2O231 (NONOate) functional group. The polymer can be applied to various medical devices for the treatment of various diseases such as thrombosis and restenosis.

Abstract: The present invention is directed to a novel poly(diol citrates)-based coating for implantable devices. More specifically, the specification describes methods and compositions for making and using implantable devices coated with citric acid copolymers or citric acid copolymers impregnated with therapeutic compositions and/or cells.

Abstract: Disclosed herein is a biodegradable nitric oxide-generating polymer comprising a nitric oxide-releasing N2O231 (NONOate) functional group. The polymer can be applied to various medical devices for the treatment of various diseases such as thrombosis and restenosis.

Abstract: Disclosed herein is a biodegradable nitric oxide-generating polymer comprising a nitric oxide-releasing N2O2? (NONOate) functional group. The polymer can be applied to various medical devices for the treatment of various diseases such as thrombosis and restenosis.

Abstract: Disclosed herein is a biodegradable nitric oxide-generating polymer comprising a nitric oxide-releasing N2O2? (NONOate) functional group. The polymer can be applied to various medical devices for the treatment of various diseases such as thrombosis and restenosis.

Abstract: Controlled release vascular implants, such as vascular grafts, stents, wraps, and gels comprising a biocompatible polymer and all trans retinoic acid (ATRA), or its derivatives, can be used to treat, prevent, or inhibit thrombosis and/or neointimal hyperplasia which may otherwise be induced by prosthetic implantation. In particular, the implants herein can inhibit smooth muscle cell proliferation, neointimal hyperplasia, and upregulate antithrombotic genes and nitric oxide production in the vasculature. Further, the implants are capable of delivering controlled and predictable localized concentrations of ATRA.